Drug Landscape ›
mouse nerve growth factor ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 10
Most-reported reactions
Abdominal Discomfort — 1 report (10%) Alanine Aminotransferase Increased — 1 report (10%) Ammonia Increased — 1 report (10%) Ascites — 1 report (10%) Aspartate Aminotransferase Increased — 1 report (10%) Blood Alkaline Phosphatase Increased — 1 report (10%) Blood Bilirubin Increased — 1 report (10%) Depressed Level Of Consciousness — 1 report (10%) Electrolyte Imbalance — 1 report (10%) Erythema — 1 report (10%)
Source database →
mouse nerve growth factor in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is mouse nerve growth factor approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for mouse nerve growth factor in United States?
Zhujiang Hospital is the originator. The local marketing authorisation holder may differ — check the official source linked above.